CHEMOTHERAPY
Online ISSN : 1884-5894
Print ISSN : 0009-3165
ISSN-L : 0009-3165
Tosufloxacin tosilate for prevention of infection inneutropenic Patients with hematological malignancies
Acomparison with polymyxin B
Ken TanakaHiroto JojimaSeishi OsabeKaori ShiraishiKazuhiko MatsuoJunichi HondaEiji NakamuraHideyo NatoriKoutaro OhizumiKiminori KogaKumiko MasuchiYutaka ImamuraKouichiro Egami
Author information
JOURNAL FREE ACCESS

1993 Volume 41 Issue 11 Pages 1183-1190

Details
Abstract

We studied the effectiveness of tosufloxacin tosilate (TFLX) in preventing infection in neutropenic patients with hematological malignancies and compared it with polymyxin B (PL-B). We randomly divided 119 patients into a PL-B group (300 mg/day), TFLX group (600 mg/day) and PL-B plus TFLX group. Patients received prophylactic treatment throughout the entire period of neutropenia until their neutrophil count exceeded 1, 000/μl. Clinical prophylactic efficacy was observed in 43.6% of the PL-B group, 73.7% of the TFLX group and 81.0% of the PL-B plus TFLX group. Efficacy was significantly higher in the TFLX group than in the PL-B group, however, difference between the TFLX group and PL-B plus TFLX group was not significant. Bacteriological effect for preventing gram-negative bacillary infection was significantly better in the TFLX group than in the PL-B group, andthere were no markeddifferencesbetween the TFLXgroup and PLB plus TFLX group. No adverse reactions or abnormal laboratory test values in response to TFLX, were observed. These findings suggest that TFLX is a more efficacious oral antimicrobial agent than PL-B. TFLX is a very useful drug which provides high prophylactic efficacy for the prevention of infection, safety, and excellent compliance in neutropenic patients with hematological malignancies.

Content from these authors
© Japanese Society of Chemotherapy
Previous article Next article
feedback
Top